Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life.

Trial Profile

Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix); Varicella zoster virus vaccine live
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
    • 01 Aug 2008 Results reported in the Pediatric Infectious Disease Journal.
    • 06 Feb 2006 Status changed fro recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top